Mix-and-match COVID vaccines trigger potent immune response
Preliminary results from a trial of more than 600 people are the first to show the benefits of combining different #COVID19 vaccines.
Vaccinating people with both the Oxford–AstraZeneca and Pfizer–BioNTech COVID-19 vaccines produces a potent immune response against the #coronavirus #SARSCoV2, researchers conducting a study in Spain have found.
Preliminary results from the trial of more than 600 people — announced in an online presentation on 18 May — are the first to show the benefits of combining different coronavirus vaccines. A UK trial of a similar strategy reported1 safety data last week, and is expected to deliver further findings on immune responses soon.
Because of safety concerns, several European countries are already recommending that some or all people who were given a first dose of the vaccine developed by the University of Oxford, UK, and AstraZeneca in Cambridge, UK, get another vaccine for their second dose. Researchers hope that such mix-and-match COVID-19 vaccination regimens will trigger stronger, more robust immune responses than will two doses of a single vaccine, while simplifying immunization efforts for countries facing fluctuating supplies of the various vaccines.
“It appears that the Pfizer vaccine boosted antibody responses remarkably in one-dose AstraZeneca vaccinees. This is all around wonderful news,” says Zhou Xing, an immunologist at McMaster University in Hamilton, Canada.
Read more at: